RxDoctor Payments Data

Gladys Moreno

Family · Bakersfield, CANPI 1023580966

Payments from drug & device makers

$6,166in general payments, 2019–2025

Across 282 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Incyte Corporation$712
  • AstraZeneca$450
  • Novartis$324
  • Blueprint Medicines Corporation$284
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,92796%
  • Education$2394%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,166 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab12$44,907
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$41,086
XolairOmalizumab14$36,049
Azelastine Hcl35$881
Montelukast Sodium48$612
Fluticasone Propionate38$611
Albuterol Sulfate HfaAlbuterol Sulfate14$397
Levocetirizine Dihydrochloride23$315
Famotidine14$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$1,355$41,08646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →